Red Spruce Capital, LLC Neurocrine Biosciences Inc Call Options Transaction History
Red Spruce Capital, LLC
- $209 Million
- Q2 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding NBIX
# of Institutions
632Shares Held
94.5MCall Options Held
505KPut Options Held
341K-
Black Rock Inc. New York, NY13.8MShares$1.99 Billion0.04% of portfolio
-
Vanguard Group Inc Valley Forge, PA9.93MShares$1.44 Billion0.03% of portfolio
-
State Street Corp Boston, MA3.99MShares$577 Million0.02% of portfolio
-
Jpmorgan Chase & CO New York, NY2.3MShares$332 Million0.03% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny2.25MShares$326 Million0.49% of portfolio
About NEUROCRINE BIOSCIENCES INC
- Ticker NBIX
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 95,639,296
- Market Cap $13.8B
- Description
- Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...